CINECA IRIS Institutional Research Information System

CARULLO, MARTINA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 997
NA - Nord America 896
EU - Europa 418
SA - Sud America 112
AF - Africa 34
Continente sconosciuto - Info sul continente non disponibili 2
Totale 2.459
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 860
SG - Singapore 390
CN - Cina 265
IT - Italia 175
HK - Hong Kong 109
BR - Brasile 92
VN - Vietnam 64
DE - Germania 62
KR - Corea 50
GB - Regno Unito 35
FI - Finlandia 31
FR - Francia 31
IN - India 29
JP - Giappone 29
NL - Olanda 13
CA - Canada 12
SE - Svezia 11
BD - Bangladesh 10
PL - Polonia 10
RU - Federazione Russa 10
AT - Austria 9
CI - Costa d'Avorio 9
MX - Messico 9
ID - Indonesia 8
ES - Italia 7
SN - Senegal 7
TR - Turchia 6
UA - Ucraina 6
VE - Venezuela 6
AR - Argentina 5
IQ - Iraq 5
LT - Lituania 5
UZ - Uzbekistan 5
PK - Pakistan 4
CZ - Repubblica Ceca 3
KE - Kenya 3
MA - Marocco 3
NI - Nicaragua 3
PH - Filippine 3
SA - Arabia Saudita 3
ZA - Sudafrica 3
AE - Emirati Arabi Uniti 2
AZ - Azerbaigian 2
BG - Bulgaria 2
CL - Cile 2
CR - Costa Rica 2
DO - Repubblica Dominicana 2
EC - Ecuador 2
EG - Egitto 2
ET - Etiopia 2
HN - Honduras 2
JO - Giordania 2
PE - Perù 2
TH - Thailandia 2
TN - Tunisia 2
UY - Uruguay 2
XK - ???statistics.table.value.countryCode.XK??? 2
AL - Albania 1
AM - Armenia 1
BY - Bielorussia 1
CH - Svizzera 1
DZ - Algeria 1
GT - Guatemala 1
HU - Ungheria 1
IE - Irlanda 1
IR - Iran 1
JM - Giamaica 1
KY - Cayman, isole 1
KZ - Kazakistan 1
LK - Sri Lanka 1
LV - Lettonia 1
MD - Moldavia 1
MQ - Martinica 1
NG - Nigeria 1
OM - Oman 1
PA - Panama 1
PR - Porto Rico 1
PT - Portogallo 1
PY - Paraguay 1
QA - Qatar 1
SY - Repubblica araba siriana 1
TG - Togo 1
TJ - Tagikistan 1
TW - Taiwan 1
Totale 2.459
Salva come PNG Salva come JPEG
Città #
Singapore 257
San Jose 189
Ashburn 158
Hong Kong 107
Dallas 91
Santa Clara 80
Hefei 75
Seoul 46
Shanghai 41
Los Angeles 38
Munich 36
Beijing 30
New York 27
Tokyo 27
Ho Chi Minh City 26
Council Bluffs 21
Turku 20
Boardman 19
Hanoi 18
Florence 16
Pisa 16
Columbus 15
London 15
Milan 15
Redondo Beach 15
Frankfurt am Main 12
Abidjan 9
Helsinki 9
São Paulo 9
Genoa 8
Lauterbourg 8
Warsaw 8
Dakar 7
Orem 7
Turin 7
Cascina 6
Hyderabad 6
Mumbai 6
Rome 6
Chicago 5
Denver 5
Fuzhou 5
Nuremberg 5
Ogden 5
Quanzhou 5
Vienna 5
Atlanta 4
Avaré 4
Bologna 4
Buffalo 4
Guarulhos 4
Jakarta 4
Manchester 4
Phoenix 4
Salerno 4
Amsterdam 3
Bexley 3
Brooklyn 3
Da Nang 3
Haiphong 3
Istanbul 3
Managua 3
Nam-gu 3
Ottawa 3
Poplar 3
Stockholm 3
Tashkent 3
Abingdon 2
Amparo 2
Araure 2
Baku 2
Bangkok 2
Bari 2
Barquisimeto 2
Basra 2
Biên Hòa 2
Castelvetro di Modena 2
Castiglione Chiavarese 2
Castiglione delle Stiviere 2
Center 2
Cesena 2
Chennai 2
Chongqing 2
Colombo 2
Dammam 2
Dehradun 2
Dhaka 2
Düsseldorf 2
Falkenstein 2
Fano 2
Guangzhou 2
Houston 2
Jersey City 2
Karachi 2
Kyiv 2
Livorno 2
Mexico City 2
Montevideo 2
Montreal 2
Nairobi 2
Totale 1.679
Salva come PNG Salva come JPEG
Nome #
Immune-Checkpoint Inhibitors (ICIs) in Metastatic Colorectal Cancer (mCRC) Patients beyond Microsatellite Instability 182
Primary tumour side as a driver for treatment choice in RAS wild-type metastatic colorectal cancer patients: a systematic review and pooled analysis of randomised trials 175
Circulating Tumor DNA as a Marker of Minimal Residual Disease After Radical Resection of Colorectal Liver Metastases 167
Surgery combined with intra-operative microwaves ablation for the management of colorectal cancer liver metastasis: A case-matched analysis and evaluation of recurrences 148
Bone metastases are associated with worse prognosis in patients affected by metastatic colorectal cancer treated with doublet or triplet chemotherapy plus bevacizumab: a subanalysis of the TRIBE and TRIBE2 trials 143
Total neoadjuvant treatment and organ preservation strategies in the management of localized rectal cancer: A narrative review and evidence-based algorithm 127
The Evolving Landscape of Immunotherapy in Locally Advanced Rectal Cancer Patients 123
Adverse events during first-line treatments for mCRC: The Toxicity over Time (ToxT) analysis of three randomised trials 123
The relative dose intensity of first-line FOLFOXIRI and FOLFOX/FOLFIRI both in combination with bevacizumab affects prognosis of metastatic colorectal cancer patients: A pooled analysis of TRIBE and TRIBE2 studies 107
The prognostic value of radiomic features in liver-limited metastatic colorectal cancer patients from the TRIBE2 study 103
Network meta-analysis of adjuvant chemotherapy in biliary tract cancers: Setting the scene for new randomized evidence 100
A constitutive interferon-high immunophenotype defines response to immunotherapy in colorectal cancer 99
Molecular screening with liquid biopsy for anti-EGFR retreatment in metastatic colorectal cancer: preliminary data from the randomized phase 2 PARERE trial 97
Liver metastases do not predict resistance to the addition of atezolizumab to first-line FOLFOXIRI plus bevacizumab in proficient MMR metastatic colorectal cancer: a secondary analysis of the AtezoTRIBE study 97
ShorTrip Trial: A Prospective, Multicentric Phase II Single-Arm Trial of Short-Course Radiotherapy Followed by Intensified Consolidation Chemotherapy With the Triplet FOLFOXIRI as Total Neoadjuvant Therapy in Locally Advanced Rectal Cancer 95
Exploring the Prognostic and Predictive Impact of Genomic Loss of Heterozygosity and Homologous Recombination Deficiency Alterations in Patients With Metastatic Colorectal Cancer 93
Induction treatment with FOLFIRINOX or oxaliplatin-based doublet followed by long-course chemoradiotherapy and surgery in locally advanced rectal cancer. A systematic review and pooled analysis from phase II and III trials 85
Primary Tumor Resection in Synchronous Metastatic Colorectal Cancer Patients Treated with Upfront Chemotherapy plus Bevacizumab: A Pooled Analysis of TRIBE and TRIBE2 Studies 84
Treatment of patients with BRAFV600E-mutated metastatic colorectal cancer after progression to encorafenib and cetuximab: data from a real-world nationwide dataset 78
Unveiling the prognostic significance of malignant ascites in advanced gastrointestinal cancers: a marker of peritoneal carcinomatosis burden 75
Benefit from upfront FOLFOXIRI and bevacizumab in BRAFV600E-mutated metastatic colorectal cancer patients: does primary tumour location matter? 66
null 35
Early-onset colorectal cancer patients exhibit a distinct molecular fingerprint: insights from a large-scale NGS study of 1209 patients 27
Circulating tumor DNA dynamics in patients with liver-limited metastatic colorectal cancer resected after first-line systemic treatment 23
Effectiveness of FTD/TPI plus bevacizumab and impact of prior bevacizumab exposure in patients with mCRC: the Italian FLOWER study 19
Upfront Modified FOLFOXIRI Plus Panitumumab for RAS/BRAF Wild-Type Metastatic Colorectal Cancer: Final Results of the Phase III TRIPLETE Study 19
null 15
Circulating Tumor DNA as a Marker of Minimal Residual Disease After Radical Resection of Colorectal Liver Metastases 3
Totale 2.508
Salva come PNG Salva come JPEG
Categoria #
all - tutte 7.282
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 7.282
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2022/202352 0 0 0 0 0 15 0 2 22 0 12 1
2023/2024186 6 10 18 9 19 24 26 4 12 13 24 21
2024/2025807 18 26 13 33 52 63 53 43 83 71 136 216
2025/20261.456 136 160 117 115 136 90 227 107 78 132 119 39
2026/20277 7 0 0 0 0 0 0 0 0 0 0 0
Totale 2.508